Slack outage stymies some business users7/24/2023 As CEOs continue to develop their COVID-Exit strategies, we analyzed how two companies have found a successful COVID-Exit path with transformations that balance portfolio moves and performance improvements. While corporate decision makers cannot plan for every potential risk, we examined some ways they can prepare for extraordinary risks, determine which protections are worth the investment, and position themselves for better resiliency. Companies have seen the effects of high-consequence, low-likelihood risks firsthand. The COVID-19 pandemic is unleashing a new era of change for businesses as well. Combined, these interventions have provided an economic buffer and some initiatives have the potential to translate into long-term solutions to protect individuals from the immediate effects of future crises. Governments across 22 countries have upped their fiscal spending as a percentage of GDP by around 20 percent compared with last year, and the private sector has made efforts to offer employee protections. New research from the McKinsey Global Institute points to another area of hope in the face of the current crisis: a renewed social contract. To boost acceptance, healthcare leaders will need to dynamically engage consumers through information campaigns using trusted, influential sources. The vast majority of US consumers surveyed believe the vaccine is important to facilitate a return to life as it was, but nearly half are “cautious adopters,” preferring to defer vaccination for up to three months to a year, after more data is available. To reach herd immunity, our analysis suggests adoption ranges would need to be greater than those of vaccines for the flu and other diseases. Stakeholders face another hurdle to widespread vaccine adoption: some consumers remain skeptical of COVID-19 immunization. Multiple vaccines and changing supply volumes will also necessitate an evolving delivery model. Governments and healthcare professionals will need to collaborate on an incredible scale to allot and deliver vaccine doses and to address challenges from storage and transport to administration and data tracking. These vaccines were developed four times faster than any other in history, but they will also require a rollout four times greater, amounting to the largest simultaneous global public-health initiative ever undertaken. The first COVID-19 vaccines have been authorized for use and dissemination has begun in several countries, marking a major turning point in the pandemic and bringing fresh optimism for a next normal in the new year. What can stakeholders do to ensure quick and effective distribution and boost public confidence in vaccination efforts? COVID-19 and the great reset: Briefing note #36, DecemVaccines are here. Please see our newest perspectives about the economic and business impact of coronavirus and how to prepare for a postpandemic world.
0 Comments
Leave a Reply. |